[1] Ghosalkar S, Singh P, Ravikumar P.Emerging topical drug delivery approaches for the treatment of Atopic dermatitis[J]. J Cosmet Dermatol, 2022, 21(2): 536-549.
[2] Frazier W, Bhardwaj N.Atopic Dermatitis: Diagnosis and Treatment[J]. Am Fam Physician, 2020, 101(10): 590-598.
[3] Harb H, Chatila TA.Mechanisms of Dupilumab[J]. Clin Exp Allergy, 2020, 50(1): 5-14.
[4] Simpson EL, Paller AS, Siegfried EC, et al.Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial[J]. JAMA Dermatol, 2020, 156(1): 44-56.
[5] Popovic B, Breed J, Rees DG, et al.Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2[J]. J Mol Biol, 2017, 429(2): 208-219.
[6] Wollenberg A, Blauvelt A, Guttman-Yassky E, et al.Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)[J]. Br J Dermatol, 2021, 184(3): 437-449.
[7] Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al.Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial[J]. JAMA Dermatol, 2020, 156(4): 411-420.
[8] Chen Y, Gutowska-Owsiak D, Hardman CS, et al.Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis[J]. Sci Transl Med, 2019, 11(515): x2945.
[9] Simpson EL, Parnes JR, She D, et al.Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial -ScienceDirect[J]. J Am Acad Dermatol, 2019, 80(4): 1013-1021.
[10] Guttman-Yassky E, Pavel AB, Zhou L, et al.GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2019, 144(2): 482-493.
[11] Nakagawa H, Iizuka H, Nemoto O, et al.Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis[J]. J Dermatol Sci, 2020, 99(2): 82-89.
[12] Dantzer JA, Wood RA.The use of omalizumab in allergen immunotherapy[J]. Clin Exp Allergy, 2018, 48(3): 232-240.
[13] Krathen RA, Hsu S.Failure of omalizumab for treatment of severe adult atopic dermatitis[J]. J Am Acad Dermatol, 2005, 53(2): 338-340.
[14] Wang HH, Li YC, Huang YC.Efficacy of omalizumab in patients with atopic dermatitis: Asystematic review and meta-analysis[J]. J Allergy Clin Immunol, 2016, 138(6): 1719-1722.
[15] Hotze M, Baurecht H, Rodriguez E, et al.Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines[J]. Allergy, 2014, 69(1): 132-135.
[16] Kang EG, Narayana PK, Pouliquen IJ, et al.Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis[J]. Allergy, 2020, 75(4): 950-953.
[17] Pan Y, Xu L, Qiao J, et al.A systematic review of ustekinumab in the treatment of atopic dermatitis[J]. J Dermatolog Treat, 2018, 29(6): 539-541.
[18] Brunner P M, Pavel A B, Khattri S, et al.Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab[J]. J Allergy Clin Immunol, 2019, 143(1): 142-154.
[19] Husein-ElAhmed H, Steinhoff M. Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence[J]. J Dermatolog Treat, 2021, 33(4): 1838-1843.
[20] Munera-Campos M, Ballesca F, Richarz N, et al.Paradoxical eczematous reaction to ixekizumab[J]. J Eur Acad Dermatol Venereol, 2019, 33(1): e40-e42.
[21] Ungar B, Pavel AB, Li R, et al.Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis[J]. J Allergy Clin Immunol, 2021, 147(1): 394-397.
[22] Kabashima K, Furue M, Hanifin JM, et al.Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study[J]. J Allergy Clin Immunol, 2018, 142(4): 1121-1130.
[23] Hanifin JM, Chan SC, Cheng JB, et al.Type 4 Phosphodiesterase Inhibitors Have Clinical and In Vitro Anti-inflammatory Effects in Atopic Dermatitis[J]. J Invest Dermatol, 1996, 107(1): 51-56.
[24] Samrao A, Berry TM, Goreshi R, et al.A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults[J]. AMA Arch Derm, 2012, 148(8): 890-897.
[25] Simpson EL, Imafuku S, Poulin Y, et al.A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis[J]. J Invest Dermatol, 2019, 139(5): 1063-1072. |
